Remaining life expectancy measurement and PSA screening of older men

Journal of Geriatric Oncology

Volumn 3, Issue 3, 2012, Pages 196-204

  Kotwal, Ashwin A ^a   Mohile, Supriya G ^b   Dale, William ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Comorbidity; NSHAP; Older adults; Prostate cancer; PSA; Remaining life expectancy; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIBODY SCREENING; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC CARE; HEALTH CARE ACCESS; HUMAN; LIFE EXPECTANCY; MALE; OUTCOME ASSESSMENT; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; SCREENING TEST; SELF CONCEPT; VALIDATION PROCESS;

EID: 84862487738     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2012.02.003     Document Type: Article

References (51)

1. Sirovich B., Schwartz L., Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA 2003, 289(11):1414.
2. Ross L., Coates R., Breen N., Uhler R., Potosky A., Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004, 38(6):732-744.
3. Finney Rutten L., Meissner H., Breen N., Vernon S., Rimer B. Factors associated with men's use of prostate-specific antigen screening: evidence from Health Information National Trends Survey. Prev Med 2005, 40(4):461-468.
4. Li J., Zhao G., Pollack L., Smith J., Joseph D. Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System. Prev Chronic Dis 2010, 7(4):1-9.
5. Dale W., Bilir P., Han M., Meltzer D. The role of anxiety in prostate carcinoma. Cancer 2005, 104(3):467-478.
6. Katz D., Jarrard D., McHorney C., Hillis S., Wiebe D., Fryback D. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 2007, 69(2):215-220.
7. Chou R., Croswell J.M., Dana T., Bougatsos C., Blazina I., Fu R., Gleitsmann K., et al. Screening for prostate cancer: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011, 155(11):762-771.
8. Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13):1310.
9. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L.J., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320.
10. Hugosson J., Carlsson S., Aus G., Bergdahl S., Khatam A., Lodding P., et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11(8):725-732.
11. Walter L., Bertenthal D., Lindquist K., Konety B. PSA screening among elderly men with limited life expectancies. JAMA 2006, 296(19):2336.
12. Arias E., Rostron B., Tejada-Vera B. United States life tables, 2005. Natl Vital Stat Rep 2005, 58(10).
13. Hoffman K., Chen M., Moran B., Braccioforte M., Dosoretz D., Salenius S., et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men 435 with high-risk prostate cancer. Cancer 2010, 116(11):2590-2595.
14. Wolf A., Wender R., Etzioni R., Thompson I., D'Amico A., Volk R., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60(2):70-98.
15. AUA Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park) 2000, 14(2):267-272.
16. USPSTF Draft recommendation statement http://www.uspreventiveservicestaskforce.org/draftrec3.htm.
17. de Groot V., Beckerman H., Lankhorst G., Bouter L., Babaian R. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003, 56:221-229.
18. Mistry S., Mayer W., Khavari R., Ayala G., Miles B. Who's too old to screen? Prostate cancer in elderly men. Can Urol Assoc J 2009, 3(3):205-210.
19. Greene K., Albertsen P., Babaian R., Cartera H., Ganna P., Hana M., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009, 182(5):2232-2241.
20. Extermann M., Overcash J., Lyman G., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16(4):1582.
21. O'Muircheartaigh C., Eckman S., Smith S. Statistical design and estimation for the national social life, health, and aging project. J Gerontol B 2009, 64(Supplement 1):i12.
22. Smith S., Jaszczak A., Graber J., Lundeen K., Leitsch S., Wargo E., et al. Instrument development, study design implementation, and survey conduct for the National Social Life, Health, and Aging Project. J Gerontol B Psychol Sci Soc Sci 2009, 64(suppl 1):i20.
23. Ross L., Taylor Y., Richardson L., Howard D. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006. J Natl Med Assoc 2009, 101(4):317.
24. Smith R.A., Cokkinides V., Brawley O.W. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009, 59(1):27.
25. Lewis C., Moore C., Golin C., Griffith J., Tytell-Brenner A., Pignone M. Resident physicians? Life expectancy estimates and colon cancer screening recommendations in elderly patients. Med Decis Making 2008, 28(2):254-261.
26. Katz J., Chang L., Sangha O., Fossel A., Bates D. Can comorbidity be measured by questionnaire rather than medical record review?. Med Care 1996, 34(1):73.
27. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
28. Idler E., Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. J Health Soc Behav 1997, 38(1):21-37.
29. Keeler E., Guralnik J., Tian H., Wallace R., Reuben D. The impact of functional status on life expectancy in older persons. J Gerontol 2010, 65(7):727-733.
30. Montero-Odasso M., Schapira M., Soriano E., Varela M., Kaplan R., Camera L., et al. Gait velocity as a single predictor of adverse events in healthy seniors aged 75 years and older. J Gerontol A Biol Sci Med Sci 2005, 60(10):1304.
31. Podsiadlo D., Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991, 39(2):142.
32. Hardy S.E., Perera S., Roumani Y.F., Chandler J.M., Studenski S.A. Improvement in usual gait speed predicts better survival in older adults. J Am Geriatr Soc 2007, 55(11):1727-1734.
33. Lynch S., Brown J., Harmsen K. The effect of altering adl thresholds on active life expectancy estimates for older persons. J Gerontol B Psychol Sci Soc Sci 2003, 58(3):S171.
34. Diehr P., Patrick D., Bild D., Burke G., Williamson J. Predicting future years of healthy life for older adults. J Clin Epidemiol 1998, 51(4):343-353.
35. Walter L., Covinsky K. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001, 285(21):2750.
36. Bohannon R. Reference values for the timed up and go test: a descriptive meta-analysis. J Geriatr Phys Ther 2006, 29(2):64.
37. Steele C., Miller D., Maylahn C., Uhler R., Baker C. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health 2000, 90(10):1595.
38. Gilligan T., Wang P., Levin R., Kantoff P., Avorn J. Racial differences in screening for prostate cancer in the elderly. Arch Intern Med 2004, 164(17):1858.
39. Lin K., Lipsitz R., Miller T., Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med 2008, 149(3):192.
40. Manzoli L., Villari P. Marital status and mortality in the elderly: a systematic review and meta-analysis. Soc Sci Med 2007, 64(1):77-94.
41. Qato D., Alexander G., Conti R., Johnson M., Schumm P., Lindau S., et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008, 300(24):2867.
42. Daskivich T., Sadetsky N., Kaplan S., Greenfield S., Litwin M. Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer. Arch Intern Med 2010, 170(15):1396.
43. Drum M., Shiovitz-Ezra S., Gaumer E., Lindau S. Assessment of smoking behaviors and alcohol use in the national social life, health, and aging project. J Gerontol B 2009, 64(Supplement 1):i119.
44. Coups E., Gaba A., Orleans C. Physician screening for multiple behavioral health risk factors. Am J Prev Med 2004, 27(2):34-41.
45. Bynum J., Song Y., Fisher E. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service medicare. J Am Geriatr Soc 2010, 58(4):674-680.
46. Han P., Coates R., Uhler R., Breen N. Decision making in prostate-specific antigen screening: National Health Interview Survey, 2000. Am J Prev Med 2006, 30(5):394-404.
47. Hoffman R., Couper M., Zikmund-Fisher B., Levin C., McNaughton-Collins M., Helitzer D., et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med 2009, 169(17):1611.
48. Hudson S., Ohman-Strickland P., Ferrante J., Lu-Yao G., Orzano A., Crabtree B. Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med 2009, 22(3):257.
49. Wilson J., Clarke M., Ewings P., Graham J., MacDonagh R. The assessment of patient life-expectancy: how accurate are urologists and oncologists?. BJU Int 2005, 95(6):794-798.
50. Chan E., Vernon S., Ahn C., Greisinger A. Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites. Am J Public Health 2004, 94(8):1336.
51. González H., West B., Underwood W. PSA testing in office-based clinics: are we testing as much as we think?. J Am Coll Surg 2005, 201(6):906-912.